Loading stock dataβ¦
Spyre Therapeutics, Inc. (SYRE)
$90.16+2.27 (+2.58%)
Market ClosedLast close Jun 29
Spyre Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD) and rheumatic diseases.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Spyre Therapeutics, Inc. in the Healthcare sector is trading at $90.16 with a market capitalization of $6.4B. Wall Street consensus targets $100.47 (15 analysts), implying a +11.4% move over the next 12 months. The stock is currently near its 52-week high of $102.06, remaining 109.0% above its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals, Altman Z in the safe zone. The Whystock Score of 85/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +11.4% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | β | β | β | β | β |
| Operating Income | -$75.64Mβ | -$57.17Mβ | -$56.89Mβ | -$51.94Mβ | -$53.57M |
| Net Income | -$69.00Mβ | -$62.53Mβ | -$11.18Mβ | -$36.72Mβ | -$44.77M |
Peer Comparison
JNJUNHPFE
Fundamentals
Spyre Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD) and rheumatic diseases. The company develops SPY001, a humanized monoclonal immunoglobulin ...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$6.38B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
3.13
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-26.75%
Volume
Today's trading volume
1.90M
Recent News
Spyre Therapeutics Stock Outlook Hinges on 2026 Study Catalysts
The investment case for Spyre Therapeutics is built around a straightforward but high-risk question: can its broad IBD pipeline produce meaningful clinical proof-of-concept data?
Spyre Therapeutics Shares Slide Following Large Insider Stock Sales (SYRE)
Spyre Therapeutics Inc. (NASDAQ:SYRE) shares dropped 13.
cAMPfield lands $180M to build gut disease drug
The biotech is advancing an anti-inflammatory drug that originated with vTv for inflammatory bowel diseases, leaning on a better side effect profile.
SYRE Completes Enrollment in SKYWAY Basket Study on SPY072, Stock Up
Spyre Therapeutics gains after completing enrollment in all SKYWAY phase II sub-studies evaluating SPY072 across three rheumatic diseases.
Spyre Therapeutics (SYRE): 12 Best High Short Interest Stocks With Highest Upside Potential
Spyre Therapeutics Inc. (NASDAQ:SYRE) is one of the best high short interest stocks with highest upside potential. On May 5, Spyre Therapeutics reported a strong Q1 2026, supported by a public offering that resulted in $1.2 billion in pro forma cash, providing a financial runway into late 2029. While R&D expenses rose to $60.4 million [β¦]